Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-70
SponsorPeking University People's Hospital
About this trial
A Clinical Study to Investigate the Safety and Efficacy of CT0890B in Patients with Relapsed/Refractory Acute Myeloid Leukemia.
Eligibility criteria
Qualifiers
Age 18-70 years (inclusive), male or female.
Relapsed or refractory acute myeloid leukemia (R/R AML) diagnosed according to the 2022 World Health Organization classification or ELN criteria, with confirmed NKG2D ligand-positive disease.
Bone marrow blasts ≥5% by morphology.
Estimated life expectancy >12 weeks.
Disqualifiers
Participants were diagnosed with acute promyelocytic leukemia (APL), BCR-ABL positive leukemia (chronic myeloid leukemia in acute phase), central nervous system leukemia;
Participants with a history of epilepsy or other central nervous system disease;
Participants who have previously received autologous or allogeneic CAR-T therapy;
Participants who have received autologous stem cell transplantation or allogeneic stem cell transplantation within 12 weeks
Trial design
Treatments tested in this trial
- CAR-T cells chimeric antigen receptor T cells
Treatment groups
27 Participants
are divided into 1 treatment groupSponsors and collaborators
Peking University People's Hospital
Lead sponsor
CARsgen Therapeutics Co., Ltd.
Collaborator
Source ClinicalTrials.gov